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Abstract: In this study, we investigated forty cyanobacterial isolates from biofilms, 
gastropods, brackish water and symbiotic lichen habitats. Their aqueous and organic 
extracts were used to screen for apoptosis-inducing activity against acute myeloid leukemia 
cells. A total of 28 extracts showed cytotoxicity against rat acute myeloid leukemia  
(IPC-81) cells. The design of the screen made it possible to eliminate known toxins, such 
as microcystins and nodularin, or known metabolites with anti-leukemic activity, such as 
adenosine and its analogs. A cytotoxicity test on human embryonic kidney (HEK293T) 
fibroblasts indicated that 21 of the 28 extracts containing anti-acute myeloid leukemia 
(AML) activity showed selectivity in favor of leukemia cells. Extracts L26-O and L30-O 
were able to partly overcome the chemotherapy resistance induced by the oncogenic 
protein Bcl-2, whereas extract L1-O overcame protection from the deletion of the tumor 
suppressor protein p53. In conclusion, cyanobacteria are a prolific resource for  
anti-leukemia compounds that have potential for pharmaceutical applications. Based on the 
variety of cellular responses, we also conclude that the different anti-leukemic compounds 
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in the cyanobacterial extracts target different elements of the death machinery of  
mammalian cells. 




Acute myeloid leukemia (AML) is characterized by excess growth of leukemia cells and loss of 
normal blood cells. Leukemia cells have no infection-fighting capacity, thus AML patients become 
susceptible to infections, as well as bruising, bleeding and shortness of breath. Nowadays, the most 
common treatment regime for AML involves high doses of the cell cycle-specific inhibitor, cytarabine 
(Ara-C), in combination with the cell cycle unspecific inhibitor, anthracycline daunorubicin  
(DNR) [1]. Recently, a few promising drug leads have been discovered to fulfill the continuous need 
of new lead compounds. An inhibitor of the Fms-like tyrosine kinase3 (FLT3) showed promising 
activity in treatment trials of patients with acute myeloid leukemia [2]. Clofarabine, a nucleoside 
antimetabolite, was tested in Phase II clinical trial of pediatric patients with relapsed or refractory 
acute leukemia [3]. Gemtuzumab ozogamicin is a drug-linked monoclonal antibody, which is used to 
treat acute myelogenous leukemia. It was recently tested in a Phase II trial of therapy in older patients 
with acute myeloid leukemia [4]. However, chemoresistance usually limits AML therapy [5,6]. Thus, 
there is a need for novel anti-leukemia drugs, particularly to be able to treat patients who tolerate 
heavy chemotherapy poorly or who are found unsuited for stem cell transplantation. 
Cyanobacteria are a large group of photosynthetic prokaryotic microorganisms, which commonly 
occur in a wide variety of environments, ranging from terrestrial, fresh, brackish to marine water. 
Some cyanobacteria live in symbioses with plants or fungi [7], and aquatic cyanobacteria are well 
known for forming blooms in eutrophic lakes and other aquatic environments. Many bloom-forming 
cyanobacteria produce toxins, such as microcystins and nodularin, which pose a health hazard to 
human and livestock [8–11]. However, cyanobacteria are able to produce a number of bioactive 
secondary metabolites having anti-tumor, anti-viral and anti-bacterial activities [12–15]. Due to the 
high diversity and chemical stability of many cyanobacterial natural products, they are promising 
candidates for pharmaceutical applications. Up to now, more than 40 anti-cancer biomolecules have 
been characterized from cyanobacteria [13], such as cryptophycins and curacins. Cryptophycins were 
tested in a Phase II trial for therapy against platinum ovarian cancer [16], and curacin A, which hinders 
tubulin polymerization [17], has been tested against breast cancer. There are many other compounds 
showing anti-cancer activity and potential for future testing in the clinical trials, such as dolastatin 10, 
malyngamide 3 and cocosamide B [18,19]. Marine cyanobacteria are considered a good source for 
novel bioactivities, and many potent bioactive compounds and drug leads have been isolated and 
identified, such as apratoxin A, bisebromoamide, coibamide and largazole [20–23]. In this study, our 
aim was to introduce an effective way to explore new anti-leukemia compounds of cyanobacteria 
isolated from biofilm, symbiotic lichen, mollusk association and brackish water habitats in order to 
find new drug leads for AML therapy. 
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2. Results and Discussion 
2.1. Results 
2.1.1. Screening Cyanobacterial Extracts for Apoptosis-Inducing Activity 
The cell line IPC-81, isolated from brown Norwegian acute myelocytic leukemia (BNML) rats, is  
a good model for AML in vivo and in vitro [24,25]. We therefore used these cells for the initial screen 
for apoptogenic activity from forty cyanobacteria strains. Eighteen strains were isolated and purified 
from biofilms from a rocky coastline, six from gastropods, two from a water plant, one from brackish 
water from the coastline of the Gulf of Finland and 13 from lichens (Table 1). 
Table 1. The cyanobacteria strain studied. All Nostoc strains are lichen symbionts. 
Coordinates: 59°49ʹ55″ N, 23°5ʹ10″ E (Kobben) and 59°49ʹ11–22″ N, 22°58ʹ34″–59ʹ10″ E 
(Hanko Casino sea shore (HC)). 
Code Genus Strain Live habitat; Location 
L1 Calothrix  HAN 24/1 Rock pond water, Kobben, Hanko, Finland 
L2 Calothrix HAN 33/2 Brown/yellow biofilm, HC, Hanko, Finland 
L3 Calothrix HAN 38/3 Red biofilm, HC, Hanko, Finland 
L4 Calothrix HAN 6/4 Growth on rock waterline, Kobben, Hanko, Finland 
L5 Calothrix HAN 17/1 Red biofilm, Kobben, Hanko, Finland 
L6 Calothrix HAN 21/4 Gastropod 10 cm under water, Kobben, Hanko, Finland 
L7 Anabaena HAN 15/1 Gastropod from waterline, Kobben, Hanko, Finland 
L8 Calothrix HAN 21/3 Gastropod 10 cm under water, Kobben, Hanko, Finland 
L9 Calothrix HAN 37/3 Green biofilm, HC, Hanko, Finland 
L10 Calothrix HAN 21/5 Gastropod 10 cm under water, Kobben, Hanko, Finland 
L11 Calothrix HAN 36/2 Biofilm, HC, Hanko, Finland 
L12 Calothrix HAN 22/1 Black biofilm, Kobben, Hanko, Finland 
L13 Calothrix HAN 22/2 Black biofilm, Kobben, Hanko, Finland 
L14 Calothrix HAN 6/3 Growth on rock waterline, Kobben, Hanko, Finland 
L15 Calothrix HAN 8/1 Biofilm, Kobben, Hanko, Finland 
L16 Calothrix HAN 38/2 Red biofilm, HC, Hanko, Finland 
L17 Calothrix HAN 3/19 Green biofilm, Kobben, Hanko, Finland 
L18 Calothrix HAN 33/1 Brown/yellow biofilm, HC, Hanko, Finland 
L19 Nodularia HAN 37/1 Green biofilm, HC, Hanko, Finland 
L20 Calothrix HAN 16/1 Waterplant from shallow water, Kobben, Hanko, Finland 
L21 Calothrix HAN 37/2 Green biofilm, HC, Hanko, Finland 
L22 Calothrix  HAN 26/2 Black biofilm, HC, Hanko, Finland 
L23 Calothrix HAN 30/2 Green biofilm and Gastropod, HC, Hanko, Finland 
L24 Calothrix HAN 20/2 Black grains from rock surface, Kobben, Hanko, Finland 
L25 Anabaena HAN 15/2 Gastropod from waterline, Kobben, Hanko, Finland 
L26 Anabaena HAN 21/1 Gastropod 10 cm under water, Kobben, Hanko, Finland 
L27 Calothrix HAN 16/2 Waterplant from shallow water, Kobben, Hanko, Finland 
L28 Nostoc UK 2aImII Peltigera sp. Helsinki, Finland 
L29 Nostoc UK 222IIc Peltigera sp. Mikkeli, Finland 
L30 Nostoc 113.5 Nephroma arcticum, Finland  
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Table 1. Cont. 
L31 Nostoc UK 92Ic Peltigera sp. Hitonhaudan rotko, Finland 
L32 Nostoc UK 89 Peltigera sp. Hitonhaudan rotko, Finland 
L33 Nostoc UK 81I Peltigera sp. Scotland 
L34 Nostoc UK 222Ib Peltigera sp. Mikkeli, Finland 
L35 Nostoc UK 60II Peltigera sp. Scotland 
L36 Nostoc N135.9.1 lichen, unknown 
L37 Nostoc N138 lichen, unknown 
L38 Nostoc UK 104 Peltigera sp. Teeri-Lososuo, Kuhmo, Finland 
L39 Nostoc UK 220Ib Peltigera sp. Mikkeli, Finland 
L40 Nostoc N134.1 lichen, unknown 
Twenty-eight extracts showed apparent apoptosis-inducing activity (a cell death rate above 30%); 
20 were aqueous extracts, and eight were organic extracts (Figure 1). Four extracts (L19-A, L30-A, 
L1-O and L26-O) induced apoptosis of IPC-81 cells by over 70%. In several strains, both extracts 
induced apoptosis, such as L1, L19, L26 and L32. This indicated either two bioactive compounds or 
one compound present in both extracts. The present selection of cyanobacteria appeared to be a good 
resource for discovering anti-AML compounds. 
In order to reveal selectivity towards leukemia cells, we next tested the extracts for apoptosis 
induction in the human embryonic kidney cell line HEK293T (Figure 2), which can indicate whether a 
compound has non-specific toxicity. Six aqueous and four organic extracts exhibited toxicity (>30% 
cell death) to HEK293T. One strain, L30, showed very strong activity in both extracts. The extracts of 
L19-A-O, L26-A-O and L36-A that induced AML-cell death exhibited no toxicity to the HEK293T 
cells. This suggested that strains L19, L26 and L36 contain one or more compounds that preferentially 
induce cell death in AML-cells. Contrary to this, the organic extracts, L17-O and L22-O, revealed 
strong toxicity towards HEK293T cells, but not towards IPC-18 cells. Based on these two screenings 
(Figures 1 and 2), we conclude that the cyanobacteria samples contained diverse bioactive compounds, 
some of which apparently are able to distinguish between AML cells and normal fibroblasts. 
2.1.2. The Detection of Known Bioactivities 
Cyanobacteria produce large amounts of bioactive compounds able to induce cell death in 
mammalian cells, such as the liver toxins, microcystins and nodularins [26–29]. We have previously 
found high amounts of the metabolite adenosine in diatoms [30] and cyanobacteria [31], and adenosine 
can induce AML cell apoptosis [32]. It was necessary to establish the presence of these activities in the 
extracts with anti-AML activity. Whereas adenosine-mediated activity can be eliminated by enzymatic 
conversion of adenosine to inosine by adenosine deaminase, the microcystin-like activity can only be 
detected by LC-MS or cell assays. 
First, adenosine deaminase was used to remove adenosine from the AML death-inducing extracts. 
We found that some, but not all, extracts lost their apoptosis-inducing ability after this treatment 
(Figure 3) and that the adenosine-like activity mostly resided in the aqueous extracts. We concluded 
that the bioactive compounds in the adenosine deaminase-resistant extracts, like L19-A, and most of 
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the organic apoptogenic extracts were unrelated to adenosine, but the activity could be due to 
adenosine analogs being resistant to adenosine deaminase. 
Figure 1. Leukemia cell death induced by cyanobacteria extracts. IPC-81 cells were 
incubated with extracts from a 5-mg biomass/mL cell suspension for 24 h before fixation in 
2% buffered formaldehyde (pH 7.4). The X-axis gives the strain numbers (see Table 1 for 
details). Cell death was assessed by microscopic assessment of the surface and nuclear 
morphology. Horizontal lines show 30% (low) and 70% (high) apoptosis levels.  
A: aqueous; O: organic. 
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Figure 2. Human embryonic kidney (HEK293T) cell death induced by cyanobacteria 
extracts. HEK293T cells were incubated with extracts from a 5-mg biomass/ml cell 
suspension for 24 h before fixation in 2% buffered formaldehyde (pH 7.4). Cell death was 
assessed by microscopic assessment of surface and nuclear morphology. Horizontal lines 
show 30% (low) and 70% (high) apoptosis levels. A: aqueous; O: organic. 
 
Figure 3. The presence of adenosine deaminase-sensitive compounds in cyanobacterial 
extracts. Cyanobacterial extracts were added to normal medium or medium containing 
adenosine deaminase and left to incubate at 30 min before the addition of IPC-81 cells. The 
cells were further incubated for 24 h before fixation and assessment of cell death, as 
described in the legend for Figure 1. As a control, adenosine was added to the medium with 
or without adenosine deaminase (left panel). 
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Although microcystins and nodularins are mainly dependent on transport into the cells to exert their 
pro-apoptotic activity, they can induce cell death in non-hepatocytes in very high concentrations. To 
ensure that we did not mistake microcystin-like activity for anti-AML activity, we took advantage of 
the need of specific transporters for such toxins to enter the cells [33,34]. Moreover, microcystin and 
nodularin induce the typical death morphology in OATP-transfected cells, with cell rounding and 
polarized budding [35]. We transfected HEK293T cells with the organic anion transporter protein, 1B3 
(OATP1B3), which increased cell sensitivity towards microcystin and nodularin. The HEK293 cells 
were chosen over IPC-81 cells, since they are easier to transfect and display a distinct morphology 
upon treatment with microcystin and nodularin (see Figure 4B,C). We used the cell death morphology 
to identify microcystin-like activity (Figure 4). This revealed microcystin-like activity in six of the 
aqueous extracts and none of the organic extracts (Table 2). Microcystin-like apoptotic activity was 
found mostly in extracts from lichen-symbiotic cyanobacteria (Tables 1 and 2). Some extracts, like 
L32-A, induced IPC-81 cell death, which could be eliminated by adenosine deaminase treatment  
(Figure 3), in addition to microcystin-like activity, evident in OATP1B3-transfected HEK293T cells 
(Figure 4E). The mild cytotoxicity seen in non-transfected HEK293T cells (Figure 2) could be a 
response to extremely high doses of microcystin or nodularin. There were also several cases where the 
cell death morphology was the same in OATP1B3 transfected and non-transfected HEK293T cells, as 
was the case for L30-A (Figure 4F). 
To confirm the presence of microcystins/nodularins, cyanobacteria extracts were analyzed with  
LC-MS (Table 2). Although there was a good overall correlation, there were some cases where the  
LC-MS data failed to match the cell-based assay. The extracts of L7-A, L36-A, L38-A, L32-O, L33-O 
and L38-O, which were shown to contain microcystin by LC-MS, had no effect on triggering the 
apoptosis of HEK293T cells. This demonstrates the strength of both methods: LC-MS has higher 
sensitivity towards toxins, can detect very low amounts and will not be affected by the presence of 
toxin inhibitors [36]. However, the cell-based assay can detect activity from unknown toxin variants. 
2.1.3. Apoptosis-Inducing Features of Cyanobacteria Extracts 
The seven most potent cyanobacteria extracts were tested to find the EC50 value in IPC-81 cells 
(Table 3). Both aqueous and organic extracts of L26 contained potent apoptosis-inducing activity and 
L26-O also exhibited the lowest EC50 among the seven extracts. In addition, L1-O and L30-A also 
showed low EC50 values against IPC-81 cells (Table 3). However, these extracts also induced 
HEK293T apoptosis at the initial screening, but this activity was not present in dilutions corresponding 
to 5–7 times the IC50 values for the IPC-81 cells (data not shown). 
To get a better impression of the anti-AML activities in the extracts, we tested the most potent 
extracts for the ability to induce cell death in the human patient-derived AML cell lines, Molm-13. 
This cell line has internal tandem duplication of the tyrosine kinase, FLT3 [37,38], which is associated 
with poor outcome and could give an indication on whether the anti-AML activity identified in the 
IPC-81 screen (Figure 1) is also active towards more malignant AML variants. We found that extracts  
L30-A and L1-O were more potent towards these cells than the rat-derived IPC-81 cells. This 
emphasizes the potential of these cyanobacterial strains to provide useful compounds in the 
development of cancer therapy. 
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Figure 4. Cell death morphology in OATP1B3-transfected HEK293T cells treated with 
cyanobacterial extracts. HEK293T cells were transfected with OATP1B3 cells, as 
described in the Methods section, and treated with 5 mg/mL cyanobacterial extracts for  
90 min before fixation in 2% buffered formaldehyde. (A,D,G) Normal morphology;  
(D,G) after treatment of extracts showing no bioactivity; (B,C) early and late apoptotic 
cells induced by 800 nM nodularin; (E) the nodularin-like response from cyanobacterial 
extract; (H) cell rounding and small blebs, which could be the signs of early apoptosis;  
(F,I) severe necrosis, perhaps induced by membrane-damaging compounds. A-extracts  
(D–G) are aqueous, and O-extracts (H,I) are organic. The scale bar represents 15 μm. 
 
Table 2. The presence of microcystin and microcystin-like activity in selected 
cyanobacteria extracts. 
Extract 
Microcystin-like activity in 
OATP-transfected HEK293 cells 
Microcystins by 
LC-MS (nM) 
L1-A − − 
L7-A − 3.9 
L9-A − − 
L12-A − − 
L19-A − − 
L20-A − − 
L26-A − − 
L30 A ND 3.8 
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Table 2. Cont. 
L31-A + 2100 
L32-A ++ 2700 
L33-A + 5100 
L35-A / 2600 
L36-A − 620 
L37-A + 13,000 
L38-A − 54 
L39-A + 2200 
L40-A + 1300 
L1-O − − 
L10-O − − 
L19-O − − 
L25-O − − 
L26-O − − 
L32-O − 43 
L33-O − 89 
L38-O − 5.6 
The + signifies the presence of bioactivity-inducing microcystin-like apoptotic morphology in  
OATP1B3-transfected HEK293 cells (second column) or the detection of microcystin or nodularin by  
LC-MS (third column). +, present, but less than 30% apoptosis; ++, strong (30%–100% apoptosis); −, absent; 
/, unknown; ND = not determined due to necrotic morphology. 
Table 3. The involvement of the chemotherapy resistance gene in apoptosis caused by 
potent cyanobacteria extracts. A comparison of the EC50 values of potent cyanobacterial 











L19-A 2.4 - 0 2.1 
L26-A >3.1 - 0 >3.1 
L30-A 0.8 - - <0.5 
L36-A >4.8 - 0 >4.8 
L1-O 0.3 - - <0.3 
L26-O <0.3 + 0 <<0.3 
L30-O ND + ND ND 
a -, extract not able to overcome resistance from Bcl-2; +, extract induces cell death also in cells 
overexpressing Bcl-2; b 0, no change in cell response dependent on the p53 status; −, absence of p53 protects 
cells from cyanobacterial extract; +, absence of P53 sensitizes cells to cyanobacterial extract;  
ND, not determined. 
We next checked whether the apoptogens of the potent cyanobacteria extracts could overcome some 
oncogenic features typical for both AML and other cancers. Bcl-2 is a key regulator of cell death, and 
the overexpression of Bcl-2 results in chemoresistance and increased tolerance to apoptogens [39]. We 
therefore tested our extracts on IPC-81 cells with enforced expression of Bcl-2 (Table 3) and found 
that these cells were resistant to all A extracts, but to a lesser degree to the O extracts from strain L26 
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and L30. This indicated that apoptosis-inducing activities in L26-O and L30-O partly overcome the 
chemotherapy resistance triggered by the overexpression of Bcl-2. It should be noted that L30-O also 
induced substantial HEK293T cell death (Figure 2). 
p53 is well known as a tumor suppressor protein, which upon DNA damage, arrests cell growth and 
initiates apoptosis. Tumor suppression is severely reduced if the TP53 gene is mutated and the  
p53 protein is deficient or absent [40]. In this experiment, we exposed the human leukemia cell line, 
Molm-13, with functional p53 (wt) or constitutively expressing siRNA against p53 mRNA (shp53). 
This could reveal if the cyanobacterial apoptogens could overcome chemoresistance in p53-deficient 
cells. We found that the cell death induced by L30-A depended on p53. On the other hand, the 
apoptogen(s) in extract 1-O were more potent in cells with reduced p53 activity than in cells with 
intact p53 (Table 3). For the other extracts, there was little change in apoptosis-induction between the 
two cell types. 
2.2. Discussion 
A high number of the cyanobacterial extracts screened in this study contained apoptosis-inducing 
activity in acute myeloid leukemia cells, and some of them were also able to overcome typical features 
related to chemotherapy resistance. Our previous screenings also showed cyanobacteria as a prolific 
source of cytotoxic and anti-leukemic activities [41–44]. In addition, the continuous discovery of novel 
compounds from cyanobacteria [45–49] and the huge biosynthetic potential based on ribosomal and 
non-ribosomal biosynthetic gene clusters discovered in recent whole genome sequencing  
projects [50,51] make cyanobacteria an important group of micro-organism to be used as a source of 
new drug leads. With the vast number of different metabolites produced by cyanobacteria, often by 
related enzymes acting in concert [52], it is likely that cyanobacteria strains with a similar genetic 
background can produce different bioactive compounds. Small changes in the structure of such a 
compound can have a major impact on the bioactivity and mechanism of action on mammalian cells. 
We detected apoptosis-inducing activity in more than fifty percent of the cyanobacteria strains 
(Figures 1 and 2) and leukemia-selective bioactivity in 28 cyanobacteria extracts. Based on resistance 
to adenosine deaminase, we concluded that the bioactivity of most of the extracts was not due to 
adenosine or its analogs [32]. We could not exclude the possibility that some of our hits may be 
adenosine analogs. However, they retained their activity after adenosine deaminase treatment, 
suggesting that they will not be metabolized by adenosine deaminase in the blood. 
Among the potent anti-leukemic cyanobacteria strains, three (L1, L19 and L26) were benthic 
marine cyanobacteria and two (L30 and L36) were from lichen. Benthic cyanobacteria have been 
previously shown to contain interesting bioactivities [41–44] in contrast to the planktonic, which often 
contain microcystins [14,15]. Lichen-associated cyanobacteria are known to produce the hepatotoxins, 
microcystins and nodularin [53], which can cause fatal injuries, such as liver damage [54], if they 
reach circulation. Despite this, we found anti-leukemic activity in lichen-associated strains (e.g., L32, 
L33, L36 and L38) (Tables 1 and 2, Figure 1) and, thus, conclude that also the lichen-associated 
cyanobacteria are a new resource for finding anti-AML compounds and could be included in screens 
for pharmaceuticals. 
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We also found two extracts, L26-O and L30-O, from strains collected from a gastropod and lichen, 
respectively, which could partly overcome the chemoresistance mediated by enforced expression of 
Bcl-2 in the IPC-81 cells (Table 3). Bcl-2 is a well-known anti-apoptotic cell factor, which could result 
in chemotherapy resistance if overexpressed in the cancer cells [55,56]. Although the  
apoptosis-inducing activities in the remaining extracts were effectively blocked by Bcl-2 (Table 3),  
we cannot exclude the possibility that these extracts contain compounds that can become important 
leads in drug development. 
Another oncogenic factor important in cancer chemotherapy is deleted or non-functional p53. In our 
study, the p53 mRNA in Molm-13 cells was silenced with the anti-sense RNA, and these cells are 
more resistant to apoptogens [57]. Interestingly, the extract, L1-O, induced more apoptosis in Molm-13 
with silenced p53 cells than the wild-type, suggesting that L1-O could overcome the chemotherapy 
resistance caused by absent or non-functional p53, which is common in several cancers [58].  
In addition, some extracts were more potent towards the Molm-13 cells than the IPC-81 cells (Table 3). 
The IPC-81 cells have a very rapid doubling rate of about 12 hours and are thus very sensitive towards 
drugs acting on the mitotic machinery. The extracts more potent towards Molm-13 cells could contain 
substances able to selectively attack the Achilles‘ heel of malignant leukemia cells [59], leaving 
normal cells, like HEK293T cells, unaffected. 
3. Experimental Section 
3.1. Reagents 
The main methanol and formaldehyde were from VWR (West Chester, NY, USA). Horse serum 
was supplied by EuroClone Life Sciences Division (Milan, Italy), and fetal bovine serum was from 
Invitrogen, (Carlsbad, CA, USA). Hoechst #33342 was from Polysciences, Inc. (Warrington, PA, 
USA). WST-1 was from Roche diagnostics (Basel, Switzerland). All other chemicals reagents, 
including cell culture media, were from Sigma (Sigma-Aldrich Co. LLC, St. Louis, MO, USA). 
3.2. Isolation, Cultivation and Identification of Cyanobacteria 
The cyanobacteria strains used in this study (see Table 1) were isolated from marine habitats  
(27 strains) and from symbiotic lichen (13 strains). The strains were identified based on their 
morphology according to Castenholz (2001) [60] and sequencing of the 16S rRNA gene, as previously 
detailed [61,62]. All cyanobacteria were grown in Z8X nitrogen free medium at 20 °C for 21 days 




. The cells were harvested by 
centrifugation at 10,000× g for 5 min. 
3.3. Preparation of Cyanobacterial Extracts for Cell Experiments 
Freeze-dried cyanobacteria biomass (20 mg) was suspended in 1.5 mL of methanol:water: 
dichloromethane (1:1:1). After homogenization, the suspensions were centrifuged for 10 min at 
20,000× g. The upper and lower layers were collected separately and the remaining pellet re-extracted 
in the same manner. The extracts from the two extractions were combined, and the aqueous and 
organic layers evaporated in a vacuum centrifuge. The aqueous extracts were dissolved in 160 µL of 
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25% aqueous DMSO, and the organic extracts were dissolved in 40 µL of 100% DMSO and kept at 
−20 °C until bioassays. 
3.4. Cell Lines and Maintenance 
The rat promyeloid leukemia wild-type cell lines, IPC-81 [24] and IPC-81 with enforced expression 
of Bcl-2 [63], were cultured in Dulbecco‘s modified Eagle‘s medium (DMEM) supplemented with 
10% (v/v) horse serum. The human acute monocytic leukemia cells, Molm-13 [37], were cultured in 
RPMI medium supplemented with antibiotics and 10% fetal bovine serum. Human embryonic kidney 
cells (HEK293T) were cultured in DMEM supplemented with 10% fetal bovine serum. When the cells 
reached 80% confluence, they were detached by mild trypsin treatment (0.33 mg·mL
−1
 trypsin for  
5 min at 37 °C), washed and reseeded in fresh medium to 25% confluence. Enforced expression of 
OATP1B3 along with green fluorescent protein (GFP) by calcium phosphate transfection of 70% 
confluent HEK293T cells for 6 h. After 20 h, the cells were detached and seeded in 48-well  
tissue culture plates (30,000 cells/well), left to attach, and experiments were conducted. The vector for  
OATP1B3 [64] was a gift from Dietrich Keppler, German Cancer Research Center, Division of Tumor 
Biochemistry, Heidelberg, Germany. All cell media were supplemented with 50 U·mL
−1
 of penicillin 
and 0.05 mg·mL
−1
 of streptomycin. 
3.5. Determination of Cell Death 
For assays of cell death, the leukemia cells were centrifuged at 160× g for 4 min, suspended in fresh 
medium, and 1.5 × 10
4
 cells were seeded in 0.1 mL in a 96-well tissue culture plate. The HEK cells 
were detached by mild trypsin treatment, centrifuged, seeded in 48 wells (30,000 cells/well) and left 
overnight to attach before experiments. Extracts, toxins or solvents were added to the cells, and the 
plates were kept at 37 °C in a humidified atmosphere with 6% CO2 overnight before stopping the 
experiment by fixation of the cells in 2% buffered formaldehyde (pH 7.4) with 0.01 mg·mL
−1
 of the 
DNA-specific fluorescent dye, Hoechst 33342. Apoptosis was scored by differential interference 
contrast and fluorescence microscopy (Axiovert 35M, Carl Zeiss, Oberkochen, Germany), as 
previously described [43]. In some experiments, the WST-1 viability assay was used to score the 
metabolic capacity of treated cells. However, when using extracts containing pigments, we found the 
microscopic analyses more reliable. 
3.6. Hydrolysis of Extracts with Adenosine Deaminase 
To eliminate adenosine from the extracts, 1 µL of organic or 4 µL of aqueous extract was added to 
50 U adenosine deaminase in a total volume of 50 µL DMEM medium. After 30 min, 50 µL of IPC-81 
cells were added and experiments conducted as described above. Adenosine deaminase itself did not 
induce apoptosis. As a positive control, we added adenosine up to 20 µM with or without adenosine 
deaminase to the cells. The adenosine deaminase completely removed the apoptotic potential  
of adenosine (Figure 3). 
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3.7. Analysis of Microcystins with LC-MS 
Between 7 and 31 mg of freeze-dried cells of forty cyanobacteria strains were extracted with  
1.5 mL extracting solvent, including methanol, water and dichloromethane, at a rate of 1:1:1.  
In addition, 200 µL of 0.5 mm glass beads (Scientific Industries, New York, NY, USA) were added in 
the 2-mL tubes for homogenization. This was carried out on a Fast Prep homogenizer (FP120, Bio 101, 
Savant) for 60 s at a speed value of 6 m·s
−1
. Extracts were centrifuged for 5 min at 20,000× g. Then, 
the upper aqueous and lower organic layer were collected and evaporated. After evaporation, the 
aqueous layer was resuspended in 25% aqueous acetonitrile, and the organic layer was dissolved in 
100% acetonitrile before LC-MS analyses. LC-MS analyses were performed with an Agilent 1100 
Series LC/MSD Ion Trap XCT Plus System (Agilent Technologies, Palo Alto, CA, USA) using a 
Phenomenex Kinetex C18 (150 × 2.1 mm, 5 µm, Phenomenex, Torrance, CA, USA) LC-column. For 
the quantification of microcystins, the extraction was made as described above, except that the organic 
extract was dissolved in 100 µL of DMSO and the aqueous extract in 160 µL of 25% DMSO. 
Microcystin-LR and Microcystin-RR were used as the standard. Analysis was done as previously 
described [65]. 
4. Conclusions 
We conclude that both marine and lichen-associated cyanobacteria can provide substances that 
eventually could become lead compounds for cancer therapy. Among the active cyanobacteria extracts, 
L26-O presented the highest apoptosis-inducing activity, could partly overcome the chemotherapy 
resistance caused by the Bcl-2 protein and was highly potent also against the human leukemia  
patient-derived cell line, Molm13. If the apoptogens in the anti-AML positive extracts could be 
isolated and identified, there could be several potent leads for developing improved cancer therapy. 
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